Affluent Medical SAS (AFME) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Affluent Medical SAS (AFME) has a cash flow conversion efficiency ratio of -0.319x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-6.74 Million ≈ $-7.88 Million USD) by net assets (€21.11 Million ≈ $24.68 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Affluent Medical SAS for the company's overall valuation and market capitalisation.
Affluent Medical SAS - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Affluent Medical SAS's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Affluent Medical SAS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Affluent Medical SAS ranked by their cash flow conversion efficiency. See Affluent Medical SAS (AFME) debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nicola Mining Inc
V:NIM
|
0.542x |
|
Evertop Wire Cable Corp
TW:1616
|
-0.093x |
|
Payton -L
TA:PAYT
|
0.009x |
|
ReaLy Development & Construction
TWO:2596
|
0.055x |
|
Indorama Synthetics Tbk
JK:INDR
|
0.050x |
|
Macauto Industrial Co Ltd
TWO:9951
|
0.065x |
|
Kangnam Jevisco Co Ltd
KO:000860
|
0.000x |
|
Global Mediacom Tbk
JK:BMTR
|
0.013x |
Annual Cash Flow Conversion Efficiency for Affluent Medical SAS (2016–2024)
The table below shows the annual cash flow conversion efficiency of Affluent Medical SAS from 2016 to 2024. View AFME stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €30.27 Million ≈ $35.39 Million |
€-11.32 Million ≈ $-13.24 Million |
-0.374x | +2.33% |
| 2023-12-31 | €31.47 Million ≈ $36.79 Million |
€-12.05 Million ≈ $-14.09 Million |
-0.383x | -16.94% |
| 2022-12-31 | €33.83 Million ≈ $39.55 Million |
€-11.08 Million ≈ $-12.95 Million |
-0.328x | -15.33% |
| 2021-12-31 | €43.53 Million ≈ $50.90 Million |
€-12.36 Million ≈ $-14.45 Million |
-0.284x | -12.16% |
| 2020-12-31 | €35.29 Million ≈ $41.26 Million |
€-8.94 Million ≈ $-10.45 Million |
-0.253x | +35.66% |
| 2019-12-31 | €30.96 Million ≈ $36.20 Million |
€-12.19 Million ≈ $-14.25 Million |
-0.394x | -122.87% |
| 2017-12-31 | €61.39 Million ≈ $71.78 Million |
€-10.84 Million ≈ $-12.68 Million |
-0.177x | +4.12% |
| 2016-12-31 | €58.87 Million ≈ $68.82 Million |
€-10.84 Million ≈ $-12.68 Million |
-0.184x | -- |
About Affluent Medical SAS
Affluent Medical SA, a medical technology company, develops and markets minimally invasive minimally invasive medical devices in the field of urology and structural heart in France. It offers Artus, an implantable electro-mechanical artificial sphincter that targets moderate to severe urinary incontinence; and Kalios and Epygon implants for the treatment of mitral insufficiency, as well as Kardio… Read more